Modality
ASO
MOA
PI3Ki
Target
GPRC5D
Pathway
RNA Splicing
Heart Failure
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jun 2026
Phase 1Current
NCT06141473
1,585 pts·Heart Failure
2018-02→2026-06·Completed
1,585 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-253mo awayInterim· Heart Failure
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Complet…
Catalysts
Interim
2026-06-25 · 3mo away
Heart Failure
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06141473 | Phase 1 | Heart Failure | Completed | 1585 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |